



## Clinical Program

## GWG Recommendations

Gil Sambrano

Vice President, Portfolio Development and Review  
California Institute for Regenerative Medicine

**TRANSFORMING**

*medicine*  
*lives*  
*futures*

June 28, 2018



# Clinical Stage Programs



CLIN 1



CLIN 2



CLIN 3

# Scoring System for Clinical Applications

- **Score of “1”**

*Exceptional merit and warrants funding.*

- **Score of “2”**

*Needs improvement and does not warrant funding at this time but could be resubmitted to address areas for improvement.*

- **Score of “3”**

*Sufficiently flawed that it does not warrant funding and the same project should not be resubmitted **for at least 6 months**.*

Applications are scored by all scientific members of the GWG with no conflict.

# CLIN1-10967: Late-Stage Preclinical Studies of Therapy for Glioblastoma

## Project Summary

<b>Therapy</b>	Genetically-modified blood stem cell transplant
<b>Indication</b>	Patients with newly diagnosed glioblastoma multiforme or grade IV glioma
<b>Goal</b>	Optimize manufacturing, conduct preclinical safety and efficacy studies, prepare IND
<b>Funds Requested</b>	\$3,684,259 (\$0 Co-funding)

Maximum funds allowable for this category: \$6,000,000

# CLIN1-10967: Late-Stage Preclinical Studies of Therapy for Glioblastoma

**GWG Recommendation:** Exceptional merit and warrants funding

Score	GWG Votes
1	10
2	2
3	2

**CIRM Team Recommendation:** Fund (concur with GWG recommendation)

**Award Amount:** \$3,684,259\*

\*Final award shall not exceed this amount and may be reduced contingent on CIRM's final assessment of allowable costs and activities.

# CLIN1-11059: Late-Stage Preclinical Studies of Therapy for Parkinson's Disease

## Project Summary

<b>Therapy</b>	Neural progenitor cells genetically modified to express GDNF
<b>Indication</b>	Mid-stage Parkinson's disease (UPDRS stage III or lower)
<b>Goal</b>	Manufacture cells, conduct long-term safety studies, demonstrate safety and tolerability in large animal model
<b>Funds Requested</b>	\$5,811,340 (\$0 Co-funding)

Maximum funds allowable for this category: \$6,000,000



# CLIN1-11059: Late-Stage Preclinical Studies of Therapy for Parkinson's Disease

**GWG Recommendation:** Exceptional merit and warrants funding

Score	GWG Votes
1	9
2	6
3	0

**CIRM Team Recommendation:** Fund (concur with GWG recommendation)

**Award Amount:** \$5,811,340\*

\*Final award shall not exceed this amount and may be reduced contingent on CIRM's final assessment of allowable costs and activities.